BofA raised the firm’s price target on Elevance Health (ELV) to $370 from $330 and keeps a Neutral rating on the shares. Managed Care payment year 2027 stars results were largely in line with expectations as a number of MCOs preannounced their ratings early, though Centene (CNC) and Elevance “showed nice improvement in their stars, albeit off of depressed bases,” the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Elevance Health price target raised to $420 from $342 at Mizuho
- Elevance Health price target raised to $395 from $373 at Barclays
- Elevance Health price target raised to $398 from $360 at Guggenheim
- Elevance Health price target raised to $412 from $330 at Wells Fargo
- Sector Spotlight: UnitedHealth shareholder proposes split of CEO, chair role